Pharma Marketing at Launch: Key Success Factors for a Strong Market Entry

A successful pharmaceutical product launch depends on careful planning long before market entry. Alongside clinical, regulatory, and logistical considerations, communication strategy plays a pivotal role. Delayed campaign rollouts, unclear responsibilities, or inefficient approval processes can cost valuable market potential and ultimately revenue. Companies that understand regulatory requirements, align timelines early, and prepare proactively create the foundation for a successful launch.

Navigating the Regulatory Landscape

Pharmaceutical launch activities are subject to strict legal and regulatory requirements. In both Germany and Austria, medicinal products may only be promoted after marketing authorization has been granted, as stipulated in Directive 2001/83/EC Art. 87(1), § 3a HWG (Germany), and § 50a(1) AMG (Austria). In addition, communication around prescription-only medicines is strictly limited to healthcare professionals (§ 10 HWG Germany; § 54 AMG Austria).

In practice, this means that marketing materials and campaign assets may be prepared prior to approval but cannot be used publicly until authorization is granted. Failure to comply with these rules can lead to legal action, jeopardize the entire launch strategy, and in severe cases delay or halt planned marketing activities altogether.

Setting the Strategic Direction Early

A smooth and effective launch requires a clearly defined marketing strategy developed well in advance. This strategy should be grounded in robust market analysis, precise audience segmentation, and strong product positioning. The medical value proposition must be translated into a consistent communication narrative, while ensuring that all market intelligence activities remain compliant with applicable advertising regulations.

During the launch phase, all activities should align around a shared objective. Companies should identify relevant KOLs, establish core messaging early, and communicate these messages internally across teams. Supported by market research, clearly defined KPIs, and a structured data strategy, organizations can steer launch activities effectively and maximize the chances of commercial success.

Leveraging Disease Awareness Before Approval

The pre-approval phase also offers opportunities for early communication initiatives. While product promotion is not yet permitted, disease-awareness campaigns can help educate stakeholders about a condition and establish a company’s presence within a therapeutic area.

As an established communication tool, disease-awareness activities can highlight unmet medical needs, explain diagnostic pathways, and contextualize treatment goals. To remain compliant, all content should be medically balanced, evidence-based, and transparent avoiding exaggerated expectations or fear-based messaging.

A critical factor is maintaining a clear separation between disease education and product promotion. The focus must remain exclusively on the disease itself. According to European Court of Justice case law (ECJ ruling of 05 May 2011 – C-316/09), communication may already qualify as advertising if it is intended to promote sales. Consequently, even communications without explicit product references may still be considered promotional. This makes compliance particularly important in the period leading up to approval. Put simply: "the closer a communication activity is to launch, the greater the likelihood that it may interpreted as promotional advertising".

Appointing the Information Officer Early

Pharmaceutical companies marketing medicinal products in Germany or Austria are required to appoint an Information Officer (“Informationsbeauftragter”, IB) under § 74a(1) AMG (Germany) and § 56(2) AMG (Austria). This individual is responsible for overseeing communications relating to the approved medicinal product, including the review and approval of promotional materials.

Although the formal obligation begins once the product is approved, appointing the Information Officer several months earlier offers significant advantages. Early onboarding allows the individual to become familiar with internal systems, processes, and launch materials ahead of time. An additional benefit is the possibility of conducting pre-reviews of marketing materials before approval. Since launch periods typically involve a high volume of simultaneous approvals, pre-reviewing materials can significantly accelerate final sign-off once authorization is granted.

Preparing the Short SmPC “At Risk”

The short SmPC required under § 4 HWG can quickly become a bottleneck during launch preparation. Marketing materials are often developed before approval, while the final mandatory wording is not yet available. After authorization, these texts must be drafted, reviewed, and incorporated into all promotional materials, potentially delaying campaign activation.

To streamline the process, many companies prepare the short SmPC “at risk” based on the draft SmPC and integrate it into materials ahead of approval. Since final changes are often minimal, the approved version can usually be reviewed and finalized quickly after authorization, helping teams save valuable time and enabling a smoother launch execution.

Establishing Approval Processes and Training Teams

Successful launches require not only strong marketing assets but also efficient internal processes. Companies should implement clear workflows for the review and approval of both promotional and non-promotional materials and document them in SOPs. These SOPs should define responsibilities, review steps, and approval criteria.

Equally important is the early training of all relevant employees. In addition to SOP training, teams should be educated on launch strategy and compliance requirements well before launch activities begin. This ensures that launch initiatives are implemented efficiently, compliantly, and with smooth cross-functional collaboration.

‍

Successful Launches Start Before Market Entry

The success of a pharmaceutical product launch is often determined well before the product reaches the market. Strategic preparation, regulatory readiness, and clearly defined operational processes are critical to ensuring a smooth and successful launch. Missing strategic alignment, unclear responsibilities, or insufficient coordination can quickly become risks that impact both launch timelines and commercial success.

In practice, a structured and well-organized approach has proven essential. To support companies during this critical phase, we work with a dedicated launch checklist designed to capture all relevant activities, identify potential bottlenecks early, and streamline preparation efforts across teams. By creating greater transparency and improving coordination between marketing, medical, regulatory, and compliance functions, this approach helps establish the foundation for a successful and efficient market entry.